Documenting Electronic Data Files and Statistical Analysis Programs; Draft Guidance for Industry; Availability; Extension of Comment Period
Health and Human Services Department; Food and Drug Administration · 2018
Read Documenting Electronic Data Files and Statistical Analysis Programs; Draft Guidance for Industry; Availability; Extension of Comment Period by Health and Human Services Department; Food and Drug Administration (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/uslaw-fr-2018-15568.txt.
Description
Notice published in the Federal Register on 2018-07-20 by Health and Human Services Department; Food and Drug Administration. Text from federalregister.gov (official edition: govinfo). [Pages 34595-34596] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2018-15568] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2009-D-0052] Documenting Electronic Data Files and Statistical Analysis Programs; Draft Guidance for Industry; Availability; Extension of Comment Period.
Catalog record
| CREATOR | Health and Human Services Department; Food and Drug Administration |
|---|---|
| YEAR | 2018 |
| COLLECTION | LAW |
| FORMAT | TXT |
| FILE SIZE | 7 KB |
| VERSION | 1.0 |
| LICENSE | Public Domain |
| RIGHTS | PUBLIC DOMAIN |
| SOURCE | Federal Register |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Documenting Electronic Data Files and Statistical Analysis Programs; Draft Guidance for Industry; Availability; Extension of Comment Period
Citation: us:fr:2018-15568
Creator: Health and Human Services Department; Food and Drug Administration
Year: 2018
Source-URL: https://www.federalregister.gov/documents/2018/07/20/2018-15568/documenting-electronic-data-files-and-statistical-analysis-programs-draft-guidance-for-industry
Context: Notice published in the Federal Register on 2018-07-20 by Health and Human Services Department; Food and Drug Administration. Text from federalregister.gov (official edition: govinfo).
[Pages 34595-34596]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-15568]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-D-0052]
Documenting Electronic Data Files and Statistical Analysis
Programs; Draft Guidance for Industry; Availability; Extension of
Comment Period
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of availability; extension of comment period.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is extending
the comment period for the notice of availability that published in the
Federal Register on May 21, 2018. In that document, FDA requested
comments on the draft revised guidance for industry (GFI) #197 entitled
``Documenting Electronic Data Files and Statistical Analysis
Programs.'' The Agency is taking this action in response to a request
for an extension to allow interested persons additional time to submit
comments.
DATES: FDA is extending the comment period on the document published
May 21, 2018 (83 FR 23468). Submit either electronic or written
comments on the draft revised guidance by October 18, 2018, to ensure
that the Agency considers your comment on this draft guidance before it
begins work on the final version of the guidance.
ADDRESSES: You may submit comments on any guidance at any time as
follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2009-D-0052 for ``Documenting Electronic Data Files and Statistical
Analysis Programs.'' Received comments will be placed in the docket
and, except for those submitted as ``Confidential Submissions,''
publicly viewable at https://www.regulations.gov or at the Dockets
Management Staff between 9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed
[[Page 34596]]
except in accordance with 21 CFR 10.20 and other applicable disclosure
law. For more information about FDA's posting of comments to public
dockets, see 80 FR 56469, September 18, 2015, or access the information
at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Virginia Recta, Center for Veterinary
Medicine (HFV-160), Food and Drug Administration, 7500 Standish Pl.,
Rockville, MD 20855, 240-402-0840, [email protected].
SUPPLEMENTARY INFORMATION: In the Federal Register of May 21, 2018, FDA
published a notice announcing the availability of draft revised GFI
#197 entitled ``Documenting Electronic Data Files and Statistical
Analysis Programs'' with a 60-day comment period. We requested comments
about informing sponsors of recommendations for documenting electronic
data files and statistical analyses submitted to CVM to support new
animal drug applications. These recommendations are intended to reduce
the number of revisions that may be required for CVM to effectively
review data submissions and to simplify submission preparation by
providing a recommended documentation framework.
The Agency has received a request for a 90-day extension of the
comment period. The request conveyed concern that the current 60-day
comment period does not allow sufficient time to develop a
comprehensive response.
FDA has considered the request and is extending the comment period
for the notice of availability for 90 days, until October 18, 2018. The
Agency believes that a 90-day extension allows adequate time for
interested persons to submit comments.
Dated: July 16, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018-15568 Filed 7-19-18; 8:45 am]